Bharat Biotech’s nasal vaccine against COVID-19 gets a nod from Central drugs panel

Bharat Biotech’s nasal vaccine against COVID-19 gets a nod from Central drugs panel

Last Updated Sep - 12 - 2022, 02:55 AM | Source : Fela News

The vaccine has been approved by CDSCO for primary immunization against Covid-19 in the age group above 18 years for restricted use in emergency situations.

New Delhi: It has come as a big boost to India's fight against Covid-19, Bharat Biotech's Chimpanzee Adenovirus Vectored recombinant nasal vaccine has been approved by Central Drugs Standard Control Organisation (CDSCO).

The vaccine has been approved by CDSCO for primary immunization against Covid-19 in the age group above 18 years for restricted use in emergency situations.

Union Health Minister Mansukh Mandaviya tweeted the news.

Big Boost to India's Fight Against COVID-19!

Bharat Biotech's ChAd36-SARS-CoV-S COVID-19 (Chimpanzee Adenovirus Vectored) recombinant nasal vaccine approved by @CDSCO_INDIA_INF for primary immunization against COVID-19 in 18+ age group for restricted use in emergency situation.

— Dr Mansukh Mandaviya (@mansukhmandviya) September 6, 2022

In another tweet, he wrote, “This step will further strengthen our collective fight against the pandemic. India has harnessed its science, R&D, and human resources in the fight against Covid-19 under PM Narendra Modi’s leadership. With the science-driven approach & Sabka Prayas, we will defeat Covid-19.”

Share :